| 【Company Research】China Meidong Auto (1268 HK) – 3Q22 operational data may beat expectation |
| 【行业研究】中国互联网行业 – 2022年AWS云科技峰会公布中国市场四项战略举措 |
| 【Sector Research】China Project Management Sector – Defaulted developers + LGFV, the new demand |
| 【Sector Research】China Property Sector – Long completion, short new start |
| 【Company Research】BeiGene (BGNE US) – Superior PFS vs ibrutinib in r/r CLL further supports the best-in-class potential of zanubrutinib |
| 【行业研究】中国互联网行业 – Meta Connect 2022: 持续迈向元宇宙愿景 |
| 【Sector Research】China Internet Sector – Meta Connect 2022: bridging the gap towards metaverse |
| 【Sector Research】China CIS Sector – Maintain long-term positive outlook; near-term challenges persist |
| 【Fixed Income Research】Asian AT1s Part I – Our picks on Chinese G-SIBs AT1s |
| 【Company Research】Biocytogen Pharmaceuticals (2315 HK) – High-throughput antibody discovery platform empowers innovation |
公司地址：香港中環花園道三號冠君大廈45-46樓
電話：（852） 3900-0888 傳真：（852） 3761-8788
招銀國際版權所有 Copyright © 2019-2026 CMB International Capital Corporation Limited. All rights reserved.
